Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
Authors
Keywords
-
Journal
CURRENT OPINION IN GASTROENTEROLOGY
Volume 38, Issue 5, Pages 521-531
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-07-27
DOI
10.1097/mog.0000000000000874
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
- (2022) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
- (2021) T. Conroy et al. ANNALS OF ONCOLOGY
- Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
- (2021) Roberto Alva-Ruiz et al. ANNALS OF SURGICAL ONCOLOGY
- A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
- (2021) Naru Kondo et al. EUROPEAN JOURNAL OF CANCER
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
- (2020) Grainne M. O'Kane et al. CLINICAL CANCER RESEARCH
- Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
- (2020) Adam R. Wolfe et al. Cancer Medicine
- Surgical Outcome Results From SWOG S1505
- (2020) Syed A. Ahmad et al. ANNALS OF SURGERY
- Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
- (2020) Giampaolo Perri et al. JAMA Surgery
- Total Neoadjuvant Therapy for Operable Pancreatic Cancer
- (2020) Rebecca Y. Kim et al. ANNALS OF SURGICAL ONCOLOGY
- A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
- (2020) D Brock Hewitt et al. ANNALS OF SURGERY
- Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
- (2020) R. Casolino et al. ANNALS OF ONCOLOGY
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
- (2020) Volker Kunzmann et al. Lancet Gastroenterology & Hepatology
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
- (2019) Mark J. Truty et al. ANNALS OF SURGERY
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer
- (2019) Janet E. Murphy et al. JAMA Oncology
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- (2018) Janet E. Murphy et al. JAMA Oncology
- A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma
- (2018) Susan Tsai et al. ANNALS OF SURGERY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
- (2016) Matthew H. G. Katz et al. JAMA Surgery
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now